Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease

“…[53] Antiviral treatment for occult hepatitis B Patients with evidence of prior HBV infection [HB core Ab-positive, HBsAg-negative] do not require antiviral prophylaxis. In an analysis of five studies on immunosuppressed IBD patients who were HB core Ab-positive, HBV reactivation occurred in 0.28% of patients [51,54,55,60,61]. In patients receiving anti-TNF agents for various conditions, including IBD, Perez-Alvarez et al found a reactivation rate of 5% [56].…”